Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.
You can find some of his selected Inquirer pieces here.
Chair, Department of Urology
Professor, Department of Urology
Roberta R. Scheller Chair in Urologic Oncology
Testicular Cancer, Bladder Cancer, Prostate Cancer, Urethral Cancer, Adrenal Tumor, Penile Cancer, Ureteral Cancer, Kidney Cancer
Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.
I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.
When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.
As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.
Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.
In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.
As part of our work, we explore the role of zinc in development and progression of prostate malignancy. Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.
The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.
In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.
Ten years ago, I figured I was the healthiest guy around.
At 73, I’m totally invested in my health and vigilant about keeping up with my doctors’ visits. When I went to my primary care physician in 2020, he alerted me that my PSA level was up, an indication that I had a problem with my prostate. I know the normal range is from 1 to 4. Mine was 5.2. “We’ll take another PSA down the road,” the doctor said. We did another one, and that was 5.6.
I’ve always been fastidious about getting my annual physical and bloodwork. Even in 2020, when COVID kept us all at home, I did a telemedicine visit. Of course, I couldn’t get bloodwork, but since I felt perfectly healthy, I just waited until my annual 2021 exam.
In 2017, I was having one of the best years of my life. I was about to turn 60, I’d lost weight, and I was feeling good and having a great time. Then, insurance stopped covering the medication I took for acid reflux and my stomach started hurting. I visited my family doctor to ask for something to control the reflux. I also asked for an ultrasound of my stomach and gallbladder, because two other members of my family had had emergency gallbladder surgery, so it was on my mind.
Dr. Kutikov has authored over 300 peer-reviewed publications. His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks. He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.
Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures that strive to improve physician education and patient care.
Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.
You can find some of his selected Inquirer pieces here.
Patient comments
FCCC & Dr. Kutikov are the BEST!
Dr. Kutikov: Thanks for your service as a true and compassionate medical professional. The LORD blessed me during my consult with you. Thanks.
Dr kutikov is THE BEST in my opinion. Caring & clear always.
Professional, courteous staff. Excellent visit with the provider who was a consultant on my medical situation.
Superb team